The Neuroethics of Biomarkers
Oxford University Press Inc (Verlag)
978-0-19-023626-7 (ISBN)
Neuroscientists are mining nucleic acids, blood, saliva, and brain images in hopes of uncovering biomarkers that could help estimate risk of brain disorders like psychosis and dementia; though the science of bioprediction is young, its prospects are unearthing controversy about how bioprediction should enter hospitals, courtrooms, or state houses. While medicine, law, and policy have established protocols for how presence of disorders should change what we owe each other or who we blame, they have no stock answers for the probabilities that bioprediction offers. The Neuroethics of Biomarkers observes, however, that for many disorders, what we really care about is not their presence per se, but certain risks that they carry. The current reliance of moral and legal structures on a categorical concept of disorder (sick verses well), therefore, obscures difficult questions about what types and magnitudes of probabilities matter. Baum argues that progress in the neuroethics of biomarkers requires the rejection of the binary concept of disorder in favor of a probabilistic one based on biological variation with risk of harm, which Baum names a "Probability Dysfunction. " This risk-reorientation clarifies practical ethical issues surrounding the definition of mental disorder in the DSM-5 and the nosology of conditions defined by risk of psychosis and dementia. Baum also challenges the principle that the acceptability of bioprediction should depend primarily on whether it is medically useful by arguing that biomarkers can also be morally useful through enabling moral agency, better assessment of legal responsibility, and fairer distributive justice. The Neuroethics of Biomarkers should be of interest to those within neuroethics, medical ethics, and the philosophy of psychiatry.
Matthew L. Baum, DPhil, is an MD-PhD trainee at Harvard & MIT within the Division of Health Sciences & Technology and the Harvard Program in Neuroscience. He earned a DPhil from Oxford via his work at the Oxford Centre for Neuroethics and the Ethox Center as a Rhodes Scholar. He holds an MSc in Neuroscience from Trinity College Dublin, where he studied as a Mitchell Scholar. He has also served as the student/post-doc representative to the board of the International Neuroethics Society.
Introduction
Chapter 1: The Biomedical Promise Of Biomarkers
Chapter 2: Bioprediction Of Brain Disorder: Definitions And Scope
PART I: REORIENTATION OF THE CONCEPT OF DISORDER
Chapter 3:"There Is More Light Here." Re-Illuminating The Categories Of Mental
Chapter 4: The Probability Dysfunction
Chapter 5: The Practical Ethics Of Predictive Markers In Diagnosis: Can Risk Banding Address The Ethical Controversy Surrounding "Psychosis Risk Syndrome" And "Preclinical Alzheimer's Disease"?
PART II: BIOPREDICTION AND MORAL RESPONSIBILITY
Chapter 6: Enhanced Responsibility: Foreseeability And New Obligations To Others
Chapter 7: Reduced Responsibility: Distinguishing Conditions In Which Biomarkers Properly Reduce Legal Responsibility
PART III: BIOPREDICTION AND SOCIETY
Chapter 8: Bioprediction And Priority
Conclusion
Appendix I
Appendix II
Appendix III
References
Index
| Erscheinungsdatum | 12.03.2016 |
|---|---|
| Reihe/Serie | Oxford Series in Neuroscience, Law, and Philosophy |
| Zusatzinfo | 1 |
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 157 x 236 mm |
| Gewicht | 499 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Neurologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie | |
| Studium ► Querschnittsbereiche ► Geschichte / Ethik der Medizin | |
| Naturwissenschaften ► Biologie ► Humanbiologie | |
| Naturwissenschaften ► Biologie ► Zoologie | |
| Sozialwissenschaften ► Soziologie | |
| ISBN-10 | 0-19-023626-4 / 0190236264 |
| ISBN-13 | 978-0-19-023626-7 / 9780190236267 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
